⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032396 | 0.85 | MEN1 (0.35) | — | |
| SCHEMBL249857 | 0.76 | — | — | |
| SCHEMBL6013334 | 0.73 | MEN1 (0.39) | — | |
| SCHEMBL10871381 | 0.69 | — | — | |
| SCHEMBL9352176 | 0.69 | MEN1 (0.46) | — | |
| SCHEMBL7485753 | 0.69 | — | — | |
| SCHEMBL572745 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL16681662 | 0.62 | — | — | |
| SCHEMBL7212924 | 0.60 | — | — | |
| SCHEMBL87312 | 0.59 | CYP3A4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2015-08-06 | — | — | US | disclosed |
| US-8912177-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2550965-A2 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORPORATION (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2209473-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | Genzyme Corporation (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009045503-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |